Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Tuesday, October 13, 2026

Back to today

Expert Call | Corning

Corning’s NVIDIA-backed 10x fiber expansion, enterprise connector demand and carrier capacity plans frame its optical communications outlook through 2030.

GLW $115B
P Equity Research 38 clicks

From X

@AsifSuria

Asif Suria on X

Sometimes we come across the same company multiple times due to different events. Noticed insider buying by a director of TechnipFMC $FTI while combing through insider transactions last night. Name rang a bell and so I looked up my brief note when I added it to my internal watchlist last year after a large stock buyback announcement. It went on to gain an additional 120% over the last year and is now up 1,163% over the last five years. And that too for an oil & gas services business.
@BrokenMoats

Broken Moats on X

Continue to believe that expiration this week will be the culmination in the software squeeze. Money will want to come off the table ahead of earnings season for the sector, and I think that will be followed with an acknowledgment from earnings that while their revenues are not at risk today - these companies still do face increased competition, lower barriers, higher costs for cloud/inference, and seat based model problems that will be challenging moving forward. The $WDAY rumor news was not the floor, it was the peak counter narrative to AI disruption.
@BrokenMoats

Broken Moats on X

Impressive just how many healthcare companies with no direct or derivative exposure today or at any point to the $MRNA news can rally 10%+ on the day. Be smart for these companies to pocket these gains with secondaries and solidify fragile balance sheets, but in the ultimate short term pump market their management teams will no doubt not want to interrupt their stocks squeeze potential and will not issue shares, but aggressively unload their options
@AsifSuria

Asif Suria on X

We track insider buying in spinoff or their parents in a custom screen on InsideArbitrage that we like to call the Spinsider. There were three companies (spinoffs or parents of spinoffs) that saw insider buying based on Form 4s filed recently. 1. The home safety and security solutions provider Resideo $RESI completed the spinoff of ADI Global Distribution $ADGI just two weeks ago. This week we saw three different insiders of $RESI buy stock on the open market including the CEO and the General Counsel. $RESI was spun out of Honeywell $HON in 2018, making $ADGI Honeywell's grandchild. 2. Enviri $NVRI was less of a spinoff and more of a breakup. It sold its Clean Earth division to to Veolia Environnement S.A. and paid out $15 per share to shareholders from the proceeds of the sale. It then spun out its Harsco Environmental and Rail divisions and renamed them as Enviri just to confuse us a little. This new Enviri saw insider buying by two insiders including the CEO this week. @valuedontlie especially likes these "stubs" as he likes to call them and has done well with stubs like Starz Entertainment $STRZ Much to my detriment, I kept Lions Gate Studios $LION after the spinoff and sold Starz. 3. The building materials company Amrize $AMRZ, which was spun out of Holcim AG in June 2025 continues to see significant insider buying activity. This month six different insiders including the CFO and the Chief Strategy & M&A Officer purchased shares.
@BlueDuckCap 1 click

BDC on X

Could happen. Also - there will be a massive 2ndary soon and insiders will start dumping shares. I wish this was a cure for cancer. It is not. If it ever even commercializes (still a big if) it will be just another thearaputic that will be sold along with Keytruda and in some cases may deter relapse. That's it. In fact, we may learn that the same lipid nano particles that the mrna technology relies on and which have been speculated to be a cancer causer in their own right (hint, they are) actually cause occurence of other cancers such as colon and pancreatic and breast. Does lowering recurrence in melanoma in exchange for a higher chance of colon cancer sound like a "cure"? I wish it was. No material position as of now. Congrats to bulls, I guess. $MRNA

Investor Letters

All letters

Vicor Update, Part Two

Vicor uses ITC exclusion-order cases to license power-module patents, with published royalty multipliers rising from 1.0x before filing to…

VICR $10B
CV's Substack 5 clicks

Expert Call | Nebius

Nebius’s 1 GW annual active-capacity target from 2027 is realistic, according to a former product manager, with greenfield data centers…

NBIS $56B
P Equity Research 5 clicks

Dell's Tailwinds

Dell booked $131.7B of AI server orders in four quarters and held a $95B backlog as enterprise AI demand accelerates.

DELL $301B
Chipstrat 4 clicks

LQDA: finer powder, higher doses

Liquidia’s Yutrepia sales reached $170.4 million in Q2 2026, while a patent ruling threatens its PH-ILD label but leaves PAH sales and a…

UTHR $24B
Trade Ideas Flow 4 clicks

“Is Ralph Lauren Still Relevant?”

Ralph Lauren’s 2017 CEO change put Patrice Louvet in charge of reversing nine quarters of same-store sales declines and restoring the…

RL $22B
TSOH Investment Research 1 click
AMADF · long

Amadeus It Group SA

Amadeus IT Group turns long after shares fell more than 20% since a November short call.

AMADF $25B
Value Investors Club 1 click

A temporary glitch?

Coupang’s November 2025 cybersecurity breach tests whether a selloff is temporary despite its 28% Korean e-commerce share, 14 million-plus…

CPNG $27B
Asian Century Stocks 9 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 52 of 238

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.